BioSpace News Archive

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ: EPRX) (TSX: EPRX) today announced its financial results for the first quarter of 2024 and provided a corporate update.

Phanes Therapeutics, Inc. (Phanes) announced today that it has entered into a clinical supply agreement with Roche to study PT217, its first-in-class bispecific antibody targeting DLL3 and CD47, in combination with Roche’s anti-PD-L1 therapy, atezolizumab, in patients with small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinomas (EP-NECs).

Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction, today announced positive preclinical data supporting the development of its lead candidate, THN391, for the treatment of neurodegenerative ocular diseases.

Global Cell Culture Market is valued at US$ 27.48 Bn in 2023, and it is expected to reach US$ 65.13 Bn by 2031, with a CAGR of 11.61 % during the forecast period of 2024-2031.

Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.

Astellas Pharma Inc. announced the opening of a new $90 million, state-of-the-art center at 480 Forbes Boulevard in South San Francisco, CA.

Gameto, a female-led biotechnology company with a mission to redefine women’s healthcare, announced new research outlining the cellular engineering and manufacturing techniques underlying Fertilo, their novel investigational in vitro maturation solution containing engineered ovarian support cells to mature eggs outside of the body.

Irvine-based Biogennix, LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products.

Erasca, Inc. provided business updates and reported financial results for the fiscal quarter ended March 31, 2024.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress.